share_log

Wedbush Maintains Outperform on Astria Therapeutics, Lowers Price Target to $18

Wedbush Maintains Outperform on Astria Therapeutics, Lowers Price Target to $18

Wedbush 维持Astria Therapeutics的跑赢大盘,将目标价下调至18美元
Benzinga ·  2023/10/13 11:22

Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and lowers the price target from $25 to $18.

Wedbush分析师劳拉·奇科维持Astria Therapeutics(纳斯达克股票代码:ATXS)跑赢大盘,并将目标股价从25美元下调至18美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发